NZ713029A - Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith - Google Patents

Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

Info

Publication number
NZ713029A
NZ713029A NZ713029A NZ71302914A NZ713029A NZ 713029 A NZ713029 A NZ 713029A NZ 713029 A NZ713029 A NZ 713029A NZ 71302914 A NZ71302914 A NZ 71302914A NZ 713029 A NZ713029 A NZ 713029A
Authority
NZ
New Zealand
Prior art keywords
joints
same
sustained release
associated therewith
pain associated
Prior art date
Application number
NZ713029A
Other languages
English (en)
Inventor
James Helliwell
Amanda Malone
Thomas Smith
Marc Baum
Original Assignee
Eupraxia Pharmaceuticals USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eupraxia Pharmaceuticals USA LLC filed Critical Eupraxia Pharmaceuticals USA LLC
Publication of NZ713029A publication Critical patent/NZ713029A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ713029A 2013-03-21 2014-03-21 Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith NZ713029A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804185P 2013-03-21 2013-03-21
PCT/US2014/031502 WO2014153541A1 (en) 2013-03-21 2014-03-21 Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

Publications (1)

Publication Number Publication Date
NZ713029A true NZ713029A (en) 2019-03-29

Family

ID=50686191

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ713029A NZ713029A (en) 2013-03-21 2014-03-21 Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

Country Status (16)

Country Link
US (6) US9987233B2 (cg-RX-API-DMAC7.html)
EP (2) EP3981388A1 (cg-RX-API-DMAC7.html)
JP (3) JP6230691B2 (cg-RX-API-DMAC7.html)
KR (2) KR102069473B1 (cg-RX-API-DMAC7.html)
CN (2) CN105517536B (cg-RX-API-DMAC7.html)
AU (2) AU2014235854B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015024234B1 (cg-RX-API-DMAC7.html)
CA (1) CA2907765C (cg-RX-API-DMAC7.html)
CL (1) CL2015002826A1 (cg-RX-API-DMAC7.html)
IL (2) IL287731B2 (cg-RX-API-DMAC7.html)
MX (1) MX378109B (cg-RX-API-DMAC7.html)
NZ (1) NZ713029A (cg-RX-API-DMAC7.html)
RU (1) RU2015144689A (cg-RX-API-DMAC7.html)
SG (2) SG10201604814WA (cg-RX-API-DMAC7.html)
TW (1) TWI686213B (cg-RX-API-DMAC7.html)
WO (1) WO2014153541A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517536B (zh) 2013-03-21 2019-08-16 优普顺药物公司美国分部 可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
SG10201902407PA (en) * 2014-09-19 2019-04-29 Eupraxia Pharmaceuticals Inc Injectable microparticles for hyper-localized release of therapeutic agents
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CN115337254A (zh) * 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017066423A1 (en) * 2015-10-13 2017-04-20 Flexion Therapeutics, Inc. Corticosteroid formulations for maintaining corticosteroid synovial fluid concentrations
BR112018008415A2 (en) 2015-10-27 2018-10-30 Eupraxia Pharmaceuticals Inc. sustained release formulations of local anesthetics
DE102016216182A1 (de) * 2016-08-29 2018-03-01 Tetec Tissue Engineering Technologies Ag Kombination, insbesondere zum Behandeln eines Knorpeldefekts
EP3595776A4 (en) * 2017-03-17 2020-09-30 Flexion Therapeutics, Inc. FLUTICASONE SUSTAINED-RELEASE FORMULATIONS AND THEIR PROCEDURES FOR USE
CN111432807A (zh) 2017-10-06 2020-07-17 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
WO2019079323A1 (en) * 2017-10-17 2019-04-25 California Institute Of Technology UNDERGROUND IMAGING OF DIELECTRIC STRUCTURES AND EMPTYES BY NARROW-BAND ELECTROMAGNETIC RESONANT DIFFUSION
CN109073743A (zh) * 2017-12-18 2018-12-21 深圳市大疆创新科技有限公司 弱目标检测方法、微波雷达传感器及无人机
CN111655303A (zh) 2018-01-08 2020-09-11 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
CN112367980A (zh) 2018-05-12 2021-02-12 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN119236191A (zh) 2018-05-24 2025-01-03 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
JP7547364B2 (ja) * 2019-04-10 2024-09-09 ユープラシア ファーマシューティカルズ インク． 所望の粒子径分布および形態の薬物結晶を作製するためのプロセス
GB202000840D0 (en) 2020-01-21 2020-03-04 Cell Guidance Systems Ltd Compositions and methods
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CN119630398A (zh) * 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
IL319996A (en) 2022-10-04 2025-06-01 Eupraxia Pharmaceuticals Inc Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract
WO2025006497A1 (en) 2023-06-26 2025-01-02 Eupraxia Pharmaceuticals Inc. Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2515898A (en) 1947-09-15 1950-07-18 Lilly Co Eli Procaine penicillin and therapeutic compositions
US2627491A (en) 1950-07-15 1953-02-03 Wyeth Corp Penicillin salts of substituted alkylene diamines
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
GB1523965A (en) 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE2805106A1 (de) 1978-02-07 1979-08-16 Hoechst Ag Mikrokapseln aus polyvinylalkohol mit fluessigem, wasserunloeslichem fuellgut und verfahren zu deren herstellung
IT1205604B (it) 1981-06-23 1989-03-23 Pierrel Spa Procedimento per la eliminazione totale o parziale di acido aspartico e acido glutammico da idrolisati proteici e micele di amminoacidi con conseguete ottenimento di miscele di aminoacidi ad alto valore nutrizionale
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4452025A (en) 1979-07-18 1984-06-05 Lew Hyok S Self-interlocking grille
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
GB2128984B (en) 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4888176A (en) 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
JPS61191609U (cg-RX-API-DMAC7.html) 1985-05-20 1986-11-28
US4940727A (en) 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5116870A (en) 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
JPS63122620A (ja) 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US5310572A (en) 1987-02-03 1994-05-10 Dow Corning Corporation Process for forming a coated active agent-containing article
US5091378A (en) 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US5017716A (en) 1987-05-22 1991-05-21 E.R. Squibb & Sons, Inc. Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method
US4904646A (en) 1987-05-22 1990-02-27 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-COA reductase inhibitors
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4997837A (en) 1987-09-08 1991-03-05 Warner-Lambert Company 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4906624A (en) 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
US4994494A (en) 1987-12-21 1991-02-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4939143A (en) 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5001144A (en) 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4900754A (en) 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US5001128A (en) 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4946864A (en) 1988-02-01 1990-08-07 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5021453A (en) 1988-03-02 1991-06-04 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
EP0331250B1 (en) 1988-03-02 1994-04-13 Merck & Co. Inc. Antihypercholesterolemic agents
US4920109A (en) 1988-04-18 1990-04-24 Merck & Co., Inc. Antifungal compositions and method of controlling mycotic infections
US5271946A (en) 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
MC2025A1 (fr) 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
US5166171A (en) 1988-05-13 1992-11-24 Hoechst Aktiengesellschaft 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiphenoxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, and in treating hypercholesterolemia
US4897402A (en) 1988-06-29 1990-01-30 Merck & Co., Inc. 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors
US4963538A (en) 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
IT1226726B (it) 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5196440A (en) 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
DE3832570A1 (de) 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
US4950675A (en) 1988-12-21 1990-08-21 Warner-Lambert Company Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis
US4957940A (en) 1988-12-21 1990-09-18 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US4906657A (en) 1988-12-21 1990-03-06 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US4923861A (en) 1989-02-07 1990-05-08 Warner-Lambert Company 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5130306A (en) 1989-03-13 1992-07-14 Merck & Co., Inc. 5-Oxygenated HMG-COA reductase inhibitors
US5132312A (en) 1989-03-27 1992-07-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4970231A (en) 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US5102911A (en) 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US4992429A (en) 1989-08-24 1991-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel HMG-COA reductase inhibitors
US5098931A (en) 1989-08-31 1992-03-24 Merck & Co., Inc. 7-substituted HMG-CoA reductase inhibitors
US4946860A (en) 1989-11-03 1990-08-07 Rorer Pharmaceutical Corporation Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors
IT1237793B (it) 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5025000A (en) 1990-03-02 1991-06-18 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitor compounds
US5084287A (en) 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5091185A (en) 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5112857A (en) 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5182298A (en) 1991-03-18 1993-01-26 Merck & Co., Inc. Cholesterol lowering agents
US5654009A (en) 1991-03-25 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Delayed action preparation
US5256689A (en) 1991-05-10 1993-10-26 Merck & Co., Inc. Cholesterol lowering compounds
US5135935A (en) 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5250435A (en) 1991-06-04 1993-10-05 Merck & Co., Inc. Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
US5202327A (en) 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
DE69223601T2 (de) 1991-08-19 1998-06-18 Eastman Kodak Co Photografisches papier mit geringer sauerstoffdurchlässigkeit
CA2079509C (en) 1991-10-01 2002-05-14 Shigeyuki Takada Prolonged release microparticle preparation and production of the same
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5260332A (en) 1992-02-07 1993-11-09 Merci & Co., Inc. Cholesterol lowering compounds
US5262435A (en) 1992-02-10 1993-11-16 Merck & Co., Inc. Cholesterol lowering compounds
US5286895A (en) 1992-02-19 1994-02-15 Merck & Co., Inc. Cholesterol lowering compounds
US5302604A (en) 1992-03-09 1994-04-12 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
US5369125A (en) 1992-07-17 1994-11-29 Merck & Co., Inc. Cholesterol-lowering agents
US5283256A (en) 1992-07-22 1994-02-01 Merck & Co., Inc. Cholesterol-lowering agents
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
CA2144407C (en) 1992-09-10 2000-05-30 Charles B. Berde Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5317031A (en) 1992-10-19 1994-05-31 Merck & Co., Inc. Cholesterol lowering compounds
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
ID21762A (id) 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
CA2407154A1 (en) 2000-04-27 2001-11-01 Verion, Inc Zero order release and temperature-controlled microcapsules and process for the preparation thereof
CA2424936A1 (en) 2000-10-06 2002-04-11 Jagotec Ag Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight
FR2816411B1 (fr) 2000-11-03 2003-07-04 Inst Nat Sante Rech Med Moyens de detection de la transformation pathologique de la proteine app et leurs applications
AR031880A1 (es) 2000-11-03 2003-10-08 Control Delivery Systems Dispositivo de liberacion sustentada implantable para administrar localmente un medicamento
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20030152637A1 (en) 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
EP1408876A4 (en) 2001-06-22 2004-09-22 Durect Corp ZERO ORDER COAXIAL IMPLANTS WITH EXTENDED RELEASE
EP1585500B8 (en) * 2002-12-20 2017-07-26 Auritec Pharmaceuticals Coated particles for sustained-release pharmaceutical administration
EP1583519A1 (en) 2002-12-20 2005-10-12 St. James Associates Llc/Faber Research Series High pressure compaction for pharmaceutical formulations
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20040191326A1 (en) 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US7063862B2 (en) 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
EP1656199B1 (en) 2003-07-31 2016-01-06 Sol-Gel Technologies Ltd. Microcapsules loaded with active ingredients and a method for their preparation
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
RU2262355C1 (ru) 2004-02-09 2005-10-20 Уракова Наталья Александровна Способ лечения артрита методом внутрисуставной инъекции суспензии лекарственных средств
CN1679515A (zh) 2004-04-06 2005-10-12 孙永海 镇痛药物缓释高分子微球及制备方法
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
WO2008048770A1 (en) 2006-10-17 2008-04-24 Lipothera, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
SE0700404L (sv) 2007-02-19 2008-08-20 Xylophane Ab Polymerfilm eller -beläggning innefattande hemicellulosa
WO2008119033A1 (en) * 2007-03-27 2008-10-02 Eurand, Inc. Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
AU2008268222B2 (en) 2007-06-25 2013-12-12 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US9637840B2 (en) * 2008-07-18 2017-05-02 Prosonix Limited Process for improving crystallinity
WO2010017265A2 (en) 2008-08-07 2010-02-11 Calosyn Pharma Injectable extended release compositions and methods of treating arthritis using same
JP2010111592A (ja) * 2008-11-04 2010-05-20 Aska Pharmaceutical Co Ltd プロピオン酸フルチカゾンを含む局所投与剤
US20110081420A1 (en) 2009-10-07 2011-04-07 Zyga Technology, Inc. Method of forming prolonged-release injectable steroids
EP2515864A4 (en) 2009-12-23 2013-09-11 Psivida Inc DELAYED RELEASE DELIVERY DEVICES
KR101423237B1 (ko) 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
CN102070895B (zh) 2010-11-17 2013-03-27 无锡中科光远生物材料有限公司 一种核壳结构微胶囊及其制备方法
JP6083936B2 (ja) 2011-03-11 2017-02-22 大阪ガスケミカル株式会社 徐放性粒子の製造方法
CA2853965A1 (en) 2011-11-03 2013-05-10 Gtx, Inc. Pharmaceutical compositions of selective androgen receptor modulators and methods of use thereof
US20150044271A1 (en) 2012-02-27 2015-02-12 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
EP3808339B1 (en) 2012-05-03 2025-11-12 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
NZ728721A (en) 2012-05-03 2018-05-25 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CN105517536B (zh) 2013-03-21 2019-08-16 优普顺药物公司美国分部 可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
SG10201902407PA (en) 2014-09-19 2019-04-29 Eupraxia Pharmaceuticals Inc Injectable microparticles for hyper-localized release of therapeutic agents
US9957233B1 (en) 2016-08-05 2018-05-01 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds

Also Published As

Publication number Publication date
EP2976062B1 (en) 2021-11-03
US20220087943A1 (en) 2022-03-24
IL287731B2 (en) 2025-05-01
JP2018052941A (ja) 2018-04-05
CA2907765C (en) 2021-07-06
WO2014153541A9 (en) 2014-11-27
EP3981388A1 (en) 2022-04-13
CN105517536B (zh) 2019-08-16
SG11201507751YA (en) 2015-10-29
RU2015144689A3 (cg-RX-API-DMAC7.html) 2018-03-19
KR20150141976A (ko) 2015-12-21
CN110575445A (zh) 2019-12-17
BR112015024234B1 (pt) 2022-11-16
CN105517536A (zh) 2016-04-20
JP6230691B2 (ja) 2017-11-15
CL2015002826A1 (es) 2016-06-03
HK1219433A1 (en) 2017-04-07
AU2014235854A1 (en) 2015-10-29
MX2015013457A (es) 2016-05-16
US20180071223A1 (en) 2018-03-15
SG10201604814WA (en) 2016-08-30
WO2014153541A1 (en) 2014-09-25
TWI686213B (zh) 2020-03-01
KR20190018763A (ko) 2019-02-25
US20180071222A1 (en) 2018-03-15
US20250090467A1 (en) 2025-03-20
KR101951075B1 (ko) 2019-02-21
KR102069473B1 (ko) 2020-01-22
AU2019204918A1 (en) 2019-07-25
CA2907765A1 (en) 2014-09-25
IL241718B (en) 2021-12-01
US20180256507A1 (en) 2018-09-13
US20140287053A1 (en) 2014-09-25
US11219604B2 (en) 2022-01-11
JP2016514728A (ja) 2016-05-23
US9987233B2 (en) 2018-06-05
MX378109B (es) 2025-03-10
RU2015144689A (ru) 2017-04-25
BR112015024234A2 (pt) 2017-07-18
IL287731A (en) 2021-12-01
CN110575445B (zh) 2023-08-18
IL287731B1 (en) 2025-01-01
TW201532633A (zh) 2015-09-01
AU2014235854B2 (en) 2019-04-11
JP6857214B2 (ja) 2021-04-14
JP2019214588A (ja) 2019-12-19
EP2976062A1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
NZ713029A (en) Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
SG10201902074UA (en) Heterocyclic compounds and uses thereof
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
NZ707477A (en) Activin-actrii antagonists and uses for treating bone and other disorders
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP3648679A4 (en) INJECTABLE ANCHORING SYSTEM AND METHODS FOR USING IT TO IMPLANT AN IMPLANTABLE DEVICE
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3041485A4 (en) Cell-seeded compositions and methods useful for treating bone regions
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
WO2015003049A3 (en) Compositions and methods to treat inflammatory joint disease
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA84310U (ru) Способ лечения гнойных кератоконъюнктивитов у котов
IN2014MU00667A (cg-RX-API-DMAC7.html)
UA105871C2 (uk) Спосіб хірургічної корекції вродженої вентральної девіації статевого члена за горпинченком-ситенком

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240229

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250301